贝利尤单抗用于儿童系统性红斑狼疮的研究进展

Recent advances in the treatment of systemic lupus erythematosus with belimumab in children

摘要:

系统性红斑狼疮（systemic lupus erythematosus，SLE）是一种累及多器官的自身免疫性疾病，狼疮肾炎（lupus nephritis，LN）是其最常见的肾脏并发症。贝利尤单抗是一种完全人源化的单克隆抗体，可减少B细胞的数量，从而减少自身抗体的形成。贝利尤单抗可改善成人和儿童SLE反应指数、SLE疾病活动度评分，延缓LN的进展，对SLE及LN的治疗具有重要作用。该文综述了国内外贝利尤单抗用于治疗儿童和成人SLE的相关研究报道，并分析了其在儿童患者中的有效性及安全性，以期能对贝利尤单抗临床应用于儿童SLE的治疗提供有效的参考价值。

Abstract:

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, and lupus nephritis (LN) is the most common renal complication of SLE. Belimumab is a fully humanized monoclonal antibody that can reduce the number of B cells, thereby reducing the formation of autoantibodies. Belimumab can improve SLE response index and SLE disease activity score and delay the progression of LN in both adults and children and thus plays an important role in the treatment of SLE and LN. This article reviews related research reports of belimumab used in the treatment of children and adults with SLE in China and overseas and analyzes the efficacy and safety of belimumab in pediatric patients, in order to provide a reference for the clinical application of belimumab in children with SLE.